Back to Search

ROBERT MASON, MD

MD

Orthopaedic Surgery Physician

NPI: 1538435581IndividualAccepts Medicare

Specialties, Licenses & Credentials

Orthopaedic Hand Surgery Physician

Orthopaedic Surgery — Hand Surgery

Code: 207XS0106X

0101263939(VA)
Orthopaedic Surgery PhysicianPrimary

Orthopaedic Surgery

Code: 207X00000X

0101263939(VA)

CMS Specialties

PrimaryORTHOPEDIC SURGERY

Education

STATE UNIVERSITY OF NY UPSTATE MEDICAL UNIVERSITY

Class of 2012

Research & Publications (20)

Evolving mechanisms of action of beta blockers: focus on nebivolol.
PMID 19528811·J Cardiovasc Pharmacol·2009
6-review
Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.
PMID 18087679·Pharm Res·2008
8-other
A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
PMID 17612051·Subcell Biochem·2007
4-observational
Targeting nitric oxide with drug therapy.
PMID 17170605·J Clin Hypertens (Greenwich)·2006
6-review
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
PMID 17126678·Am J Cardiol·2006
4-observational
Nitric oxide mechanisms in the pathogenesis of global risk.
PMID 16894246·J Clin Hypertens (Greenwich)·2006
6-review
Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
PMID 16891916·J Cardiovasc Pharmacol·2006
7-preclinical
Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity.
PMID 16785833·J Cardiovasc Pharmacol·2006
8-other
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
PMID 16503869·Curr Drug Targets Cardiovasc Haematol Disord·2005
6-review
A rationale for combination therapy in risk factor management: a mechanistic perspective.
PMID 16356809·Am J Med·2005
8-other
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
PMID 16126019·Am J Cardiol·2005
6-review
Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress.
PMID 15173061·Circulation·2004
6-review
Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.
PMID 14512371·Arterioscler Thromb Vasc Biol·2003
6-review
Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research.
PMID 12740551·Cerebrovasc Dis·2003
6-review
Membrane microdomains and vascular biology: emerging role in atherogenesis.
PMID 12732593·Circulation·2003
6-review
X-ray diffraction analysis of membrane structure changes with oxidative stress.
PMID 12152219·Methods Mol Biol·2002
8-other
Endoscopic augmentation of the cardia with a biocompatible injectable polymer (Enteryx) in a porcine model.
PMID 11928013·Surg Endosc·2002
7-preclinical
Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine.
PMID 11705416·Am J Cardiol·2001
6-review
Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease.
PMID 11560191·Pharmacotherapy·2001
6-review
[Membrane biophysical interaction of amlodipine and antioxidant properties].
PMID 11002854·Drugs·2000
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
TIDEWATER ORTHOPAEDICS, 901 ENTERPRISE PARKWAY, SUITE 900
HAMPTON, VA 23666

Location

Practice Location

TIDEWATER ORTHOPAEDICS, HAMPTON, VA
(757) 827-2480

Quick Facts

NPI
1538435581
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
2
Locations
1
Years in Practice
14
Publications
20

Are you this provider?

Claim Your Profile